将下一代树突状细胞疫苗纳入当前癌症免疫治疗领域。

Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

机构信息

Cell Death Research and Therapy (CDRT) Laboratory, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.

de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.

出版信息

Trends Immunol. 2017 Aug;38(8):577-593. doi: 10.1016/j.it.2017.05.006. Epub 2017 Jun 10.

DOI:10.1016/j.it.2017.05.006

PMID:28610825

Abstract

Cancer immunotherapy is experiencing a renaissance spearheaded by immune checkpoint inhibitors (ICIs). This has spurred interest in 'upgrading' existing immunotherapies that previously experienced only sporadic success, such as dendritic cells (DCs) vaccines. In this review, we discuss the major molecular, immunological, and clinical determinants of existing first- and second-generation DC vaccines. We also outline the future trends for next-generation DC vaccines and describe their major hallmarks and prerequisites necessary for high anticancer efficacy. In addition, using existing data we compare DC vaccines with ICIs targeting CTLA4, PD1, and PD-L1, and argue that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.

摘要

癌症免疫疗法正在经历一场由免疫检查点抑制剂 (ICIs) 引领的复兴。这激发了人们对“升级”现有免疫疗法的兴趣，这些免疫疗法以前只取得了零星的成功，如树突状细胞 (DC) 疫苗。在这篇综述中，我们讨论了现有第一代和第二代 DC 疫苗的主要分子、免疫学和临床决定因素。我们还概述了下一代 DC 疫苗的未来趋势，并描述了它们具有高抗癌疗效所需的主要特征和前提条件。此外，我们利用现有数据将 DC 疫苗与针对 CTLA4、PD1 和 PD-L1 的 ICIs 进行比较，并认为在各种情况下，下一代 DC 疫苗已经准备好应对当前 ICIs 面临的一些挑战，因此需要将 DC 疫苗纳入未来的组合免疫治疗方案中。